Rilzabrutinib

Overview

Rilzabrutinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL3702854).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Rilzabrutinib expires 20 Feb 2041 and exclusivity 29 Aug 2032. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

(E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Canonical SMILES

CC(C)(/C=C(\C#N)/C(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N)N6CCN(CC6)C7COC7

InChIKey

LCFFREMLXLZNHE-GBOLQPHISA-N